{"id":9944,"date":"2026-05-02T14:44:28","date_gmt":"2026-05-02T11:44:28","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9944"},"modified":"2026-05-02T14:44:28","modified_gmt":"2026-05-02T11:44:28","slug":"apob-vs-ldl-c-for-lipid-targets-jama-2026","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/apob-vs-ldl-c-for-lipid-targets-jama-2026\/","title":{"rendered":"ApoB vs LDL-C for Lipid Targets (JAMA 2026)"},"content":{"rendered":"<p><strong>ApoB vs LDL-C for Lipid Targets (JAMA 2026)<\/strong><\/p>\n<p>\u2022\u2060 \u2060ApoB-guided therapy &gt; LDL-C for outcomes<br \/>\n\u2022\u2060 \u2060Prevented ~1000 added events \/ 250,000 patients<\/p>\n<p>Key Findings<br \/>\n\u2022\u2060 \u2060Better CV outcomes<br \/>\n\u2022\u2060 \u2060Cost-effective (~$30K\/QALY)<br \/>\n\u2022\u2060 \u2060Requires more intensive therapy<\/p>\n<p>Clinical Insight<br \/>\n* ApoB reflects the number of atherogenic particles; even if each particle carries less cholesterol, a higher number increases the chance of arterial deposition and cardiovascular risk.<br \/>\n* Useful when LDL looks normal but risk remains high.<\/p>\n<p>Limitations \/ Barriers<br \/>\n\u2022\u2060 \u2060Not routine in lipid panel<br \/>\n\u2022\u2060 \u2060Requires extra test<br \/>\n\u2022\u2060 \u2060Practice change takes time, even with strong evidence.<\/p>\n<p>\ud83c\udfaf Take-Home<br \/>\nApoB may be better treatment target than LDL-C<br \/>\nFuture: more intensive &amp; earlier lipid lowering<\/p>\n<p>Source: JAMA<br \/>\nPublished: April 2026,<br \/>\nMedscape (April 24, 2026)<\/p>\n<p><a href=\"https:\/\/www.medscape.com\/viewarticle\/apolipoprotein-b-outperforms-traditional-targets-lipid-2026a1000d6f\">https:\/\/www.medscape.com\/viewarticle\/apolipoprotein-b-outperforms-traditional-targets-lipid-2026a1000d6f<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ApoB vs LDL-C for Lipid Targets (JAMA 2026) \u2022\u2060 \u2060ApoB-guided therapy &gt; LDL-C for outcomes \u2022\u2060 \u2060Prevented ~1000 added events \/ 250,000 patients Key Findings \u2022\u2060 \u2060Better CV outcomes \u2022\u2060 \u2060Cost-effective (~$30K\/QALY) \u2022\u2060 \u2060Requires more intensive therapy Clinical Insight * ApoB reflects the number of atherogenic particles; even if each particle carries less cholesterol, a [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9944","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9944"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9944\/revisions"}],"predecessor-version":[{"id":9945,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9944\/revisions\/9945"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}